Elafin

Specification

• Cat#: THP-0201
• Product Name: Elafin
• Description: The product is a human protein that is produced naturally in the skin, lung and breast, protecting the respective tissue from destruction by the immune system. Its ability to block the activity of destructive enzymes that are involved in inflammatory reactions makes it a highly promising active compound for the treatment of inflammatory lung diseases or severe reperfusion injuries occurring after heart attacks, serious injuries and organ transplantation.
• Sequences: Not Available
• Species: Human
• Molecular Weight: Not Available
• Purity: >99% by SDS-Page and HPLC analysis
• Cas No: Not Available
• Formula: Not Available
• Endotoxin Level: <0.001 EU per 1 μg of the peptide by the LAL method

Pharmaceutical Information

• Pharmaceutical Application: Elafin
• Applications: Investigated for use/treatment in inflammatory disorders (unspecified).
• Examples of Clinical Use: Inflammatory disorders (unspecified)
• Pharmacodynamics: Not Available
• Mechanism of action: Elafin is able to abrogate lipopolysaccharide-induced production of monocyte chemotactic protein 1 in monocytes by inhibiting AP-1 and NFkappaB activation. Due to its selective expression at mucosal surfaces as well as in alveolar macrophages, monocytes and neutrophils, the ability of Elafin to inhibit the lipopolysaccharide signaling pathway may be important in disease states such as cystic fibrosis, pneumonia, and acute respiratory distress syndrome. The inhibition of two key inflammatory pathways confirms the importance of Elafin as a mediator of the innate immune response.
• Affected organisms: Not Available
• Targets: Target 1. Neutrophil elastase; Target 2. Myeloblastin